Skip main navigation

Oral Formulation of Angiotensin-(1–7) Improves Lipid Metabolism and Prevents High-Fat Diet–Induced Hepatic Steatosis and Inflammation in Mice

Originally published 2013;62:324–330


Angiotensin (Ang)-(1–7) has been described as an important tool on treating and preventing metabolic disorders. In this study, we aimed to evaluate the effect of an oral formulation of Ang-(1–7) included in hydroxypropylβ-cyclodextrin (HPβCD/Ang-[1–7]) on hepatic function, steatosis, and on liver inflammatory markers expression in mice treated with a high-fat diet. Male FVB/N mice were divided into 4 groups and fed for 60 days, with each group receiving 1 of the following diets: standard diet+HPβCD, standard diet+Ang-(1–7)/HPβCD, high-fat diet+HPβCD, or high-fat diet+Ang-[1–7]/HPβCD. Body weight, food intake, and blood parameters, such as total cholesterol, triglyceride, alaninetransaminases, and aspartate transaminases, were evaluated. Immunohistochemical analyses were performed for inflammatory markers tumor necrosis factor-α and interleukin-6. Expression of angiotensin converting enzyme, angiotensin-converting enzyme-2, interleukin-1β, tumor necrosis factor-α, interleukin-6, transforming growth factor-β, acetyl-CoA carboxylase, carbohydrate-responsive element–binding protein, peroxisome proliferator–activated receptor-γ, and sterol regulatory element–binding proteins-1c was evaluated by quantitative real-time polymerase chain reaction. The major findings of our study included reduced liver fat mass and weight, decreased plasma total cholesterol, triglyceride, and alaninetransaminase enzyme levels in the oral Ang-(1–7)–treated groups compared with the control groups. These results were accompanied by a significant reduction in tumor necrosis factor-α and interleukin-6 mRNA expression in the liver. Analyses of liver adipogenesis-related genes by quantitative real-time polymerase chain reaction showed that acetyl-CoA carboxylase, peroxisome proliferator–activated receptor-γ, and sterol regulatory element–binding proteins-1c mRNA expression were significantly suppressed. In conclusion, we observed that treatment with Ang-(1–7) improved metabolism and decreased proinflammatory profile and fat deposition in liver of mice.


Obesity is characterized by an increase in white adipose tissue mass, which can result from an excess of food (energy) intake or altered energy expenditure.1 Obesity has been recently described as a systemic and local adipose proinflammatory state, and has been implicated in the development of common medically important complications, including hepatic steatosis, insulin resistance, and atherosclerosis.24 Classic markers of the obesity-induced inflammatory state include the augmented tissue and circulating levels of proinflammatory enzymes, procoagulant factors, cytokines, and chemokines.4,5

Hepatosteatosis is the process describing the abnormal retention of lipids within a liver cell. It reflects an impairment of the normal processes of synthesis and elimination of triglyceride fat and is commonly associated to lose of hepatocyte function. There are several different causes of hepatosteatosis, including chronic alcohol consumption, B and C viral hepatitis, type 2 diabetes mellitus, obesity, and some metabolic aberrations.6,7 Actually, fatty liver disease is considered the most prevalent form of hepatosteatosis associated with obesity and metabolic syndrome.8,9

The renin-angiotensin system (RAS) is now recognized to play an important role in the development of cardiovascular and metabolic disorders.1013 The RAS consists primarily of an enzymatic cascade in which angiotensinogen is converted to angiotensin (Ang) I and subsequently to Ang II by the actions of renin and Ang-converting enzyme (ACE), respectively.14 Ang-(1–7) is formed mainly from Ang II by ACE-2 and indirectly from Ang I.14 The ACE-2/Ang-(1–7)/Mas axis has been suggested as an important counter-regulatory arm in the RAS with effects opposing those of ACE/Ang II/Ang II receptor, type 1.13

Recent studies showed an important participation of RAS in the nonalcoholic fatty liver disease (NAFLD) development and progression. The Ang II has been implicated as a major player in the altered hepatic lipid metabolism observed in NAFLD. Genetic disruption of several RAS components in rodent models results in a protection from high-fat diet (HFD)–induced obesity.1517 In fact, knockout of renin,16 ACE,17 and liver-specific deletion of Ang II receptor type 118 also reduces hepatic steatosis in rodent models.

The role of Ang-(1–7) in metabolic regulation has been recently described. A recent study showed that Mas receptor deficiency in FVB/N mice induce dyslipidemia, lower glucose tolerance and insulin sensitivity, hyperinsulinemia, hyperleptinemia, decreased glucose uptake in white adipose cells, and an increase in adipose tissue mass.1113 These observations suggest that chronic deficiency in Ang-(1–7)/Mas axis components can lead to a metabolic syndrome-like state. More recently, 2 different studies demonstrated that transgenic rats with high-circulating Ang-(1–7) plasma levels had improved lipid and glucose metabolism associated with decreased liver gluconeogenesis.11,19

The pharmacological potential of Ang-(1–7) was significantly increased after the development of a new oral formulation characterized by a protected Ang-(1–7) molecule incorporated in acyclic-oligosaccharides (cyclodextrin). This novel compound was denominated hydroxypropylβ-cyclodextrin [HPβCD]/Ang-(1–7).2022 A pharmacokinetic test was conducted in rats to estimate the bioavailability of the compound, showing that oral formulation significantly increased plasma levels of Ang-(1–7) 12-fold over baseline with the observation for 6 hours after its administration22 (detailed Material is available in the online-only Data Supplement).

Importantly, the potential mechanism underlying the fat hepatoprotective effects of Ang-(1–7) included in HPβCD/Ang-(1–7) in vivo still remains unclear. Thus, the purpose of this study is to evaluate the effect of oral administration of Ang-(1–7) on hepatic functions and on the expression of liver inflammatory markers in mice consuming a HFD.


An expanded Methods section, detailing the techniques and procedures performed, is provided in online-only Data Supplement.


The experiment was conducted with 32 male FVB/N mice divided into 4 groups (n=8) and fed the following experimental diets, respectively, for 8 weeks: standard diet (ST)+HPβCD, ST+Ang-(1–7)/HPβCD, HFD+HPβCD, and HFD Ang-(1–7)/HPβCD: 0.1 mg/kg (HFD+Ang-[1–7]). An additional experiment with 2 groups (ST with or without Ang-[1–7]/HPβCD, 0.1 mg/kg) was conducted to evaluate a possible consequence of this compound in nonobese mice (these data are provided in the online-only Data Supplement).


Obesity was induced in male FVB/N mice by HFD (24.55% of carbohydrate, 14.47% of protein, and 60.98% of fat, presenting a total of 5.28 kcal/g of diet). Control group was fed ST (50.30% of carbohydrate, 41.90% of protein, and 7.80% of fat with a total of 2.18 kcal/g of diet).

Measurements of Body Weight, Food Intake, and Tissue Collection

Food intake and body weight were measured twice a week during treatment. Tissues were collected and stored after euthanization.

Determination of Blood Measurements

Total serum cholesterol, triglycerides, high-density protein, and aspartate and alaninetransaminases were assayed using specifics enzymatic kits.

Reverse Transcription and Real-Time Polymerase Chain Reaction

Expression of ACE, ACE-2, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, acetyl-CoA carboxylase, transforming growth factor-β, carbohydrate-responsive element–binding protein, peroxisome proliferator–activated receptor-γ and sterol regulatory element–binding protein-1c (SREBP-1c) was evaluated by quantitative real-time polymerase chain reaction.23

Histology and Oil Red O Staining

Liver samples from mice were stained with hematoxylin and eosin and Oil Red, and evaluated under a conventional light microscope.

Immunohistochemical Reactions

Immunohistochemical reactions were performed for markers IL-6 and TNF-α.

Statistical Analysis

Data are expressed as the mean±SEM. The statistical significance of differences in mean values between mice groups was assessed by 1-way ANOVA followed by Bonferroni post-test.


To examine the functional consequences of the oral treatment with Ang-(1–7), we studied the relationship between body and fat weight. Differences in body weight or food intake (g/body weight in grams) did not display differences between groups (Figure S1A and S1B in the online-only Data Supplement). However, analysis of the total fat mass (sum of adipose tissues: epididymal, mesenteric, and retroperitoneal) showed that HFD+Ang-(1–7) group exhibited a substantial decrease in fat mass (ST, 2.56±1.39; HFD, 3.80±1.27; HFD+Ang-[1–7], 2.07±0.59; 100 g/body weight in grams) in relation to HFD group (Figure S1C).

HFD+Ang-(1–7) mice exhibited a significant decrease in total cholesterol (ST, 117.3±29.32; HFD, 167.2±38.87; HFD+Ang-[1–7], 112.0±17.91) and triglyceride (HFD, 206.9±54.18 versus HFD+Ang-[1–7], 140.6±21.62) compared with HFD group (Figure 1A and 1B). In addition, Ang-(1–7) treatment plasma high-density lipoprotein increase when compared with HFD group (ST, 28.20±4.77; HFD, 18.02±9.81; HFD+Ang-[1–7], 29.94±5.95; Figure 1C).

Figure 1.

Figure 1. Plasmatic parameters. A, Total cholesterol. B, Triglycerides. C, High-density lipoprotein. D, Alanine transaminase. E, Aspartate (AST). Control mice (white bars), mice fed a high-fat diet (HFD; gray bars), or mice fed an angiotensin (Ang)-(1–7)–supplemented HFD (HFD+Ang-[1–7]; black bars) for 8 weeks. *P<0.05, **P<0.01 between HFD vs HFD+Ang-(1–7) and standard diet (ST).

Hepatic function analyses showed that alaninetransaminases serum levels were lower in ST and HFD+Ang-(1–7) when compared with HFD group (ST, 33.09±6.78; HFD, 54.66±11.71; HFD+Ang-[1–7], 32.81±4.53). Serum aspartate aminotransferase levels were lower in HFD+Ang-(1–7) when compared with the ST group (ST, 31.80±6.76; HFD, 48.14±7.51; HFD+Ang-[1–7], 39.67±6.59; Figure 1D and 1E).

In addition, analysis showed that HFD+Ang-(1–7) group has a substantial decrease in the total liver weight in HDF+Ang-(1–7) (ST, 0.035±0.0027; HFD, 0.046±0.0059; HFD+Ang-[1–7], 0.039±0.0039) in relation to HFD (Figure 2A). Hence, we performed a histological analysis to examine the effect of Ang-(1–7) on the development of fatty liver. Large hepatic lipid droplets were diffusely present in the livers of the HFD group mice compared with the other groups (Figure 2B).

Figure 2.

Figure 2. Hepatic parameters. A, Liver total weight (g/100 g body weight). B, Hematoxylin and eosin (HE) staining and Oil Red O staining. Scale bar, 50 µm. Control mice (white bars), mice fed a high-fat diet (HFD; gray bars), or mice fed an angiotensin (Ang)-(1–7)–supplemented HFD (HFD+Ang-[1–7]; black bars) for 8 weeks. *P<0.05, ***P<0.001 between HFD vs HFD+Ang-(1–7) and standard diet (ST).

Analyses of mRNA expression of adipogenesis-related genes showed that acetyl-CoA carboxylase, peroxisome proliferator–activated receptor-γ, and SREBP-1c mRNA expression in the liver were significantly suppressed in HFD+Ang-(1–7) group in comparison with the HFD group (Figure 3A and 3C). However, the expression of carbohydrate-responsive element–binding protein did not display differences among groups (Figure S2A).

Figure 3.

Figure 3. Effects of 8-week angiotensin (Ang)-(1–7) treatment on gene expression levels of lipid metabolism of the liver and renin-angiotensin system components in mice fed a high-fat diet (HFD). A, Acetyl-CoA carboxylase (ACC). B, Peroxisome proliferator–activated receptor (PPAR)-γ. C, Sterol regulatory element–binding protein-1c (SREBP-1c). D, Ang I–converting enzyme (ACE). E, ACE-2. Control mice (white bars), mice fed a HFD (gray bars), or mice fed an Ang-(1–7)–supplemented HFD (HFD+Ang-[1–7]; black bars) for 8 weeks. *P<0.05, **P<0.01 between HFD vs HFD+Ang-(1–7) and standard diet (ST).

Analysis of the expression of RAS components showed decreased levels of ACE in HDF+Ang-(1–7) mice (HFD, 1.19±0.35 versus HDF+Ang-[1–7], 0.65±0.19; Figure 3D). In addition, significantly increased expression of ACE-2 (HFD, 0.86±0.07 versus HDF+Ang-[1–7], 1.32±0.35) in HDF+Ang-[1–7] mice was observed (Figure 3E).

The mRNA expression of proinflammatory cytokines by quantitative real-time polymerase chain reaction in liver showed a significant decrease of IL-6 (ST, 0.68±0.081; HFD, 1.07±0.17; HDF+Ang-[1–7], 0.75±0.18) and TNF-α (ST, 1.01±0.4; HFD, 1.52±0.17; HDF+Ang-[1–7], 0.73±0.15) in HFD+Ang-(1–7) group (Figure 4A and 4B). The expression of the transforming growth factor-β and IL-1β did not differ among the groups (Figure S2B and S2C). Immunohistochemical reactions showed decreased expression of IL-6 and TNF-α in ST and HFD+Ang-(1–7) mice in relation to HFD mice (Figure 4C and 4D).

Figure 4.

Figure 4. Effects of 8-week angiotensin (Ang)-(1–7) treatment on gene expression inflammatory markers by real-time polymerase chain reaction and imunohistochemistry in mice fed a high-fat diet (HFD). A and C, Interleukin (IL)-6. B and D, Tumor necrosis factor (TNF)-α. Control mice (white bars), mice fed a HFD (gray bars), or mice fed an Ang-(1–7)–supplemented HFD (HFD+Ang-[1–7]; black bars) for 8 weeks. *P<0.05, **P<0.01 between HFD vs HFD+Ang-(1–7) and standard diet (ST).

Treatment of nonobese mice with Ang-(1–7)/HPβCD (0.1 mg/kg) did not alter body weight, body fat, serum lipid levels, glycemia, and hepatic enzymes (Figures S3 and S4).


In this study, we evaluated for the first time the effects of oral Ang-(1–7) administration in high-fat–induced steatosis, liver metabolism, and inflammation. We observed an important reduction in fat mass, liver weight, and hepatic steatosis associated with decreased circulating total cholesterol, triglyceride, and alaninetransaminase enzyme; improved lipid metabolism; and decreased expression proinflammatory cytokines. These effects were associated with beneficial regulation of the RAS genes expression.

Despite unchanged food intake and body weight, mice exhibited a significant decrease in fat mass. Previous studies have demonstrated the prejudicial effects of HFD on fat and metabolic performance.2427 The absence of alterations in food intake indicates that the difference in fat mass was not induced by decreased appetite and was probably caused by changes in metabolic regulation.13 Previous studies also showed a beneficial metabolic role of Ang-(1–7) in body fat mass.1113

The RAS exerts significant effects on body weight in rodents.1113 An important human study showed reduced white adipose tissue angiotensinogen levels by −27%, renin by −43%, and ACE activity by −12% after reduction of 600 kcal in daily caloric intake.28 Another study showed that Mas-knockout mice have a substantial increase in fat mass in relation to wild-type FVB/N mice with similar diameter of the adipocytes among groups, indicating that the increase in adipose tissue mass was not a result of hypertrophy in adipocytes but probably hyperplasia.12

Several studies have documented the possible role of decreased liver fatty acid oxidation in the development and progression of NAFLD and hypothesized that impaired mitochondrial function may be involved.2931 In summary, these studies showed that decreased hepatic mitochondrial fatty acid oxidation was associated with increased hepatic triacylglycerol accumulation. Supporting these data, HFD-induced obesity in mice was associated with increased hepatic peroxisome proliferator–activated receptor-γ, carnitine palmitoyltransferase-1, and acetyl-CoA carboxylase, and these changes were associated with decreased serum triacylglycerol.32 Furthermore, ACE knockout mice exhibit increased whole-body energy expenditure and increased liver expression of genes involved in fatty acid oxidation,17 supporting a direct role of Ang II in regulating fatty acid oxidation. Our study corroborate these findings once we showed that administration of Ang-(1–7) can lead to a decrease in the expression of genes related to hepaticmitochondrial fatty acid oxidation, with acetyl-CoA carboxylase and peroxisome proliferator–activated receptor-γ.

Diet-induced obesity is largely caused by disorders of fat metabolism, resulting in a massive accumulation of fat in several tissues. Lipid and energy metabolism are regulated by a complex network of signaling processes, and we, therefore, investigated mRNA expression of key genes regulating lipid metabolism. Decreased total cholesterol and triglyceride levels were shown in rats with increased circulating Ang-(1–7).12 A possible explanation would be decreased levels of mRNA expression in genes encoding lipogenic proteins, such as SREBP-1c. The lipogenic transcription factor, SREBP-1c, plays a crucial role in regulating fatty acid synthesis, and SREBP-1c–responsive major genes encode a rate-limiting enzyme in de novo fatty acid biosynthesis.3336 SREBP-1c is activator of the complete program of cholesterol and fatty acid synthesis in the liver. Thus, Ang-(1–7) can have an effect on de novo lipogenesis and lipid metabolism in liver.

Several studies reported that TNF-α, IL-6, and IL-1β are increased in obesity and this increase is correlated with numerous metabolic disorders.13 In patients with obesity, adipose and liver tissues are characterized by high-intensity inflammation and increased secretion of cytokines.37 TNF-α, IL-6, and IL-1β may be the most pernicious because they alter adipose tissue function, influencing adipogenesis, and are involved in the metabolic complications of obesity with NAFLD.38

TNF-α is a cytokine that plays a critical role in systemic and local inflammation that is produced by activated macrophages and other cell types under various pathophysiological states. With the association of obesity and NAFLD in the metabolic syndrome, it is not surprising that increased serum and liver TNF-α expression is observed in patients39 and rodent models of NAFLD.40,41

Several data suggested the involvement of TNF-α and IL-6 in the metabolic syndrome and progression of NAFLD, perhaps, in part through increased mitochondrial dysfunction and activation of fibrogenesis.42,43 TNF-α also can contribute to the development of insulin resistance through disruption of the insulin signaling cascade at the level of insulin receptor substrate-1 pathway by Ang II.44 Ang II–infused rats presented increased IL-6 expression in the liver with associated increase in monocyte recruitment and overall inflammation.45 A recent study showed that Ang-(1–7) was able to reduce inflammatory markers in rats with diabetic nephropathy.46 These data were supported by a study that revealed different molecular approaches for Ang-(1–7)–modulated inflammatory responses in mouse peritoneal macrophages, decreasing IL-6 and TNF-α.47 A more recent work has demonstrated that high-circulating Ang-(1–7) exerts significant anti-inflammatory effects by decreasing the expression of inflammatory markers in adipose tissue of high-fat–treated rats.13 A limitation of this study was not to have evaluated the direct effect of HFD on tissue Ang-(1–7) levels. However, our main focus was to evaluate the ability of oral administration of Ang-(1–7) preventing inflammation and liver steatosis and metabolism.

In conclusion, this study shows that oral treatment with Ang-(1–7) offers a protective effect against the proinflammatory response profile in the liver and improves lipid metabolism in an obese mouse model induced by a HFD. In mice treatments, Ang-(1–7) reduced fat mass, liver weight, total cholesterol, triglycerides, alaninetransaminase enzymes, and improved lipid metabolism decreasing expression proinflammatory cytokines in HFD-fed mice. These effects were associated with beneficial regulation of RAS genes with increased ACE-2 and decreased ACE expression. These results support the hypothesis of the use oral Ang-(1–7) as a novel therapeutic agent for the prevention and treatment of obesity-related disorders and fat-liver diseases.


The oral formulation of Ang-(1–7) completely prevented fat deposition in liver and improved metabolic profile. Thus, our current findings confirm and extend previous data demonstrating the great participation of Ang-(1–7) in the lipid and glucose metabolism. Altogether, these results suggest that oral formulation of Ang-(1–7) could be considered as a putative new and innovative therapeutic drug for the treatment of liver steatosis and obesity-associated diseases.


The online-only Data Supplement is available with this article at

*J.D.F. and J.M.O.A. contributed equally to this article.

Correspondence to Sérgio Henrique Sousa Santos, Department of Pharmacology, Universidade Federal de Minas Gerais, Av Antonio Carlos 6627-ICB, 31270-901, Belo Horizonte, MG, Brazil. E-mail ; or Robson Augusto dos Santos, Laborátorio de Hipertensão, Departamento de Fisiologia e Biofísica, Universidade Federal de Minas Gerais, Av Antonio Carlos 6627-ICB, 31270-901, Belo Horizonte, MG, Brazil. E-mail


  • 1. Haslam DW, James WP. Obesity.Lancet. 2005; 366:1197–1209.CrossrefMedlineGoogle Scholar
  • 2. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis.Nat Rev Cardiol. 2009; 6:399–409.CrossrefMedlineGoogle Scholar
  • 3. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance.Gastroenterology. 2007; 132:2169–2180.CrossrefMedlineGoogle Scholar
  • 4. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver—the link between adipocytes and hepatocytes.Digestion. 2011; 83:124–133.CrossrefMedlineGoogle Scholar
  • 5. Hotamisligil GS. Inflammation and metabolic disorders.Nature. 2006; 444:860–867.CrossrefMedlineGoogle Scholar
  • 6. Clément S, Negro F. Hepatitis C virus: the viral way to fatty liver.J Hepatol. 2007; 46:985–987.CrossrefMedlineGoogle Scholar
  • 7. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice.J Hepatol. 2006; 44:197–208.CrossrefMedlineGoogle Scholar
  • 8. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease.Diabetes Obes Metab. 2011; 13:692–702.CrossrefMedlineGoogle Scholar
  • 9. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome.Curr Gastroenterol Rep. 2008; 10:73–80.CrossrefMedlineGoogle Scholar
  • 10. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1–7) and its receptor as a potential targets for new cardiovascular drugs.Expert Opin Investig Drugs. 2005; 14:1019–1031.CrossrefMedlineGoogle Scholar
  • 11. Santos SH, Braga JF, Mario EG, Pôrto LC, Rodrigues-Machado Mda G, Murari A, Botion LM, Alenina N, Bader M, Santos RA. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7).Arterioscler Thromb Vasc Biol. 2010; 30:953–961.LinkGoogle Scholar
  • 12. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Pôrto LC, Alvarez-Leite JI, Botion LM, Bader M, Alenina N, Santos RA. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism.Diabetes. 2008; 57:340–347.CrossrefMedlineGoogle Scholar
  • 13. Santos SH, Fernandes LR, Pereira CS, Guimarães AL, de Paula AM, Campagnole-Santos MJ, Alvarez-Leite JI, Bader M, Santos RA. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet.Regul Pept. 2012; 178:64–70.CrossrefMedlineGoogle Scholar
  • 14. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes.Trends Endocrinol Metab. 2005; 16:120–126.CrossrefMedlineGoogle Scholar
  • 15. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance.Diabetes. 2005; 54:991–999.CrossrefMedlineGoogle Scholar
  • 16. Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, Bartness TJ, Kim HS, Harp JB. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin.Cell Metab. 2007; 6:506–512.CrossrefMedlineGoogle Scholar
  • 17. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance.Proc Natl Acad Sci USA. 2008; 105:6531–6536.CrossrefMedlineGoogle Scholar
  • 18. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis.J Hepatol. 2009; 50:1226–1235.CrossrefMedlineGoogle Scholar
  • 19. Bilman V, Mares-Guia L, Nadu AP, Bader M, Campagnole-Santos MJ, Santos RA, Santos SH. Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7).Peptides. 2012; 37:247–251.CrossrefMedlineGoogle Scholar
  • 20. Lula I, Denadai AL, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, Heine T, Duarte HA, Santos RA, Sinisterra RD. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies.Peptides. 2007; 28:2199–2210.CrossrefMedlineGoogle Scholar
  • 21. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD, Santos RA. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect.Clinics (Sao Paulo). 2011; 66:837–841.CrossrefMedlineGoogle Scholar
  • 22. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, Melo MB, Nadu AP, Souza LE, Irigoyen MC, Almeida AP, Santos RA. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats.Hypertension. 2011; 57:477–483.LinkGoogle Scholar
  • 23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods. 2001; 25:402–408.CrossrefMedlineGoogle Scholar
  • 24. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats.FASEB J. 2005; 19:136–138.CrossrefMedlineGoogle Scholar
  • 25. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.Am J Physiol Gastrointest Liver Physiol. 2006; 290:G852–G858.CrossrefMedlineGoogle Scholar
  • 26. Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A, Galinier A, Casteilla L, Leverve XM. Effects of a high-fat diet on energy metabolism and ROS production in rat liver.J Hepatol. 2011; 54:348–356.CrossrefMedlineGoogle Scholar
  • 27. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.J Clin Invest. 2003; 112:1821–1830.CrossrefMedlineGoogle Scholar
  • 28. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system.Hypertension. 2005; 45:356–362.LinkGoogle Scholar
  • 29. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.Hepatology. 2006; 43(2 suppl 1):S99–S112.CrossrefMedlineGoogle Scholar
  • 30. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.Hepatology. 2010; 52:774–788.CrossrefMedlineGoogle Scholar
  • 31. Pessayre D, Fromenty B. NASH: a mitochondrial disease.J Hepatol. 2005; 42:928–940.CrossrefMedlineGoogle Scholar
  • 32. Rong X, Li Y, Ebihara K, Zhao M, Kusakabe T, Tomita T, Murray M, Nakao K. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.Br J Pharmacol. 2010; 160:1796–1807.CrossrefMedlineGoogle Scholar
  • 33. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE, Kordari P, Chirala SS, Heird WC, Wakil SJ. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis.Proc Natl Acad Sci USA. 2006; 103:8552–8557.CrossrefMedlineGoogle Scholar
  • 34. Abu-Elheiga L, Wu H, Gu Z, Bressler R, Wakil SJ. Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.J Biol Chem. 2012; 287:12578–12588.CrossrefMedlineGoogle Scholar
  • 35. Fernández-Alvarez A, Alvarez MS, Gonzalez R, Cucarella C, Muntané J, Casado M. Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha).J Biol Chem. 2011; 286:21466–21477.CrossrefMedlineGoogle Scholar
  • 36. Foufelle F, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c.Biochem J. 2002; 366(Pt 2):377–391.CrossrefMedlineGoogle Scholar
  • 37. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue.J Clin Invest. 2003; 112:1785–1788.CrossrefMedlineGoogle Scholar
  • 38. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.Hepatology. 2010; 52:1836–1846.CrossrefMedlineGoogle Scholar
  • 39. Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.Hepatology. 2001; 34:1158–1163.CrossrefMedlineGoogle Scholar
  • 40. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.Liver Int. 2009; 29:988–996.CrossrefMedlineGoogle Scholar
  • 41. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells.J Biol Chem. 2006; 281:35137–35146.CrossrefMedlineGoogle Scholar
  • 42. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis.N Engl J Med. 2000; 343:1467–1476.CrossrefMedlineGoogle Scholar
  • 43. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.Mediators Inflamm. 2009; 2009:831670.CrossrefMedlineGoogle Scholar
  • 44. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease.Hepatology. 2005; 42:987–1000.CrossrefMedlineGoogle Scholar
  • 45. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.Am J Physiol Gastrointest Liver Physiol. 2009; 296:G147–G156.CrossrefMedlineGoogle Scholar
  • 46. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, et al. Angiotensin-(1–7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.Am J Physiol Renal Physiol. 2012; 302:F1606–F1615.CrossrefMedlineGoogle Scholar
  • 47. Hasegawa Y, Kurachi M, Okuyama S, Araki H, Otomo S. 5-HT3 receptor antagonists inhibit the response of kappa opioid receptors in the morphine-induced Straub tail.Eur J Pharmacol. 1990; 190:399–401.CrossrefMedlineGoogle Scholar

Novelty and Significance

What Is New?

  • This study shows for the first time that an oral formulation of angiotensin-(1–7) is able to prevent fat-liver steatosis in high-fat–treated animals.

What Is Relevant?

  • The present results are extremely relevant once obesity, hypertension, and diabetes mellitus are the 3 main findings in metabolic syndrome, which is the most common clinical state associated with fat-liver steatosis.


We showed that oral Angiotensin-(1–7) produced an important reduction in total body fat mass, liver weight, and hepatic steatosis, associated with decreased circulating total cholesterol, triglyceride, and alanine transaminase enzyme, and improved lipid metabolism with decreased expression of proinflammatory cytokines. These effects were associated with beneficial regulation of the renin-angiotensin system genes expression.


eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.